Rural CT Examination and Thrombolytic Treatment for Stroke (RURALCT)
Rural CT Examination and Thrombolytic Treatment for Stroke: An Observational Study of Medical and Health Economic Effects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Buskerud
-
Honefoss, Buskerud, Norway, 3004
- Vestre Viken Hospital Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Intervention group (access to local CT):
Patients from the municipalities Hol, Ål, Gol, Hemsedal and Nes.
Control group (no local CT):
Patients from the municipalities Nore and Uvdal, Vang, Øystre- and Vestre Slidre, Lesja, Skjåk, Lom, Dovre, Vågå and Sel.
Description
Inclusion Criteria:
- Patients over 18 years being investigated by CT within 24 hours for acute symptoms of stroke.
- Fullfilling criteria for the diagnosis acute stroke as described by the Norwegian stroke registry.
- Giving informed consent.
Exclusion Criteria:
- Symptoms not due to ischaemic or haemorrhagic stroke as adjudicated at discharge.
- Not able to cooperate to 3 months follow up.
- Not giving informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål.
Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
|
Rural computer tomography for acute stroke
Other Names:
|
|
2
Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning.
Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Thrombolytic treatment
Time Frame: 3 months
|
The proportion of patients with ischaemic stroke receiving thrombolytic treatment in percent.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ictus to needle time
Time Frame: 3 months
|
Time from onset of stroke symptoms (Ictus) to thrombolytic treatment (Needle).
|
3 months
|
|
Functional status
Time Frame: 3 months
|
Modified Rankin Scale (mRS score 0-6).
Good outcome 0-2
|
3 months
|
|
Cognitive status
Time Frame: 3 months
|
Montreal Cognitive Assessment (MoCA score 0-30).
Good outcome 26-30
|
3 months
|
|
Depression
Time Frame: 3 months
|
Geriatric depression scale (GDS score 0-30).
Good outcome 0-10
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jorgen M Ibsen, MD, Vestre Viken Hospital Trust
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REK 2017/102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.